Home » Newsletters » BioWorld Science

BioWorld Science

May 6, 2009

View Archived Issues

Data reported on two novel non-nucleoside HCV polymerase inhibitors -- VCH-222 and VCH-916

AT-406 shows synergistic antitumor activity with chemotherapy agents in vitro and in vivo

Memantine alleviates chronic pelvic pain symptoms in phase II trial; interim results presented

Adenoviral delivery of CD-40 ligand shows activity in patients with chronic lymphocytic leukemia

A recent Shionogi patent describes novel antibacterial agents

Takeda discloses new fatty acid amide hydrolase inhibitors

Xoma completes enrollment in phase I XOMA-052 program for type 2 diabetes

BD and Fujirebio sign biomarker assay agreement to improve cancer detection

Data confirms once-daily profile of LCP-Tacro extended-release tacrolimus

First quarter update from Chugai

Small stockpiles of an alternative drug may reduce resistance in influenza pandemic

E-10030 plus ranibizumab may cause regression of neovascular degeneration; phase I data disclosed

AL-8309A, a novel serotonin 5-HT1A agonist, presented as candidate for AMD therapy

Gabapentin enacarbil improves disease symptoms and sleep quality in restless legs syndrome

Ingenium claims novel CDK9 inhibitors that function as analgesics

Positive findings for QR-333 in diabetic peripheral neuropathy

Ghrelin receptor antagonists for the treatment of obesity described by AstraZeneca

Zoraxel improves erectile function in phase IIa study

CF-101 fails to meet endpoint in phase IIb rheumatoid arthritis study

Novel oncolytic compounds under early development at Merck KGaA

Bayer's low-dose contraceptive patch begins phase III

TZP-102 begins phase II study in diabetic patients with gastroparesis

AzaSite begins phase II program for blepharitis

AX-200 begins phase II efficacy trial for acute ischemic stroke

FDA grants orphan drug designation to Pervasis' Vascugel

Potentia reports results from phase I clinical trial of POT-4 in AMD

DMC recommends continuation of phase III SPEAR trial of Poniard's picoplatin in SCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...